In Brief: Penederm
This article was originally published in The Tan Sheet
Penederm: Benzylamine (KP 363) NDA for athlete's foot was accepted for filing on June 6 in the U.S. and Canada, the company announces June 6. Penederm submitted the NDA in the U.S. on April 6 ("The Tan Sheet" May 8, 1995, p. 19). The company plans to conduct claim-support studies against other currently marketed anti-fungal products to compare dosage, drying time, and rate of action. Penederm said it plans to file additional applications for treatment of tinea corporis and tinea cruris "later this year." Benzylamine initially will enter the market as a prescription drug; the company said it hopes to make a lower dose available OTC "as soon as possible." The product will be marketed by Schering-Plough...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC